PMA
P180038: LIAISON XL MUREX Anti-HBc, LIAISON MUREX Control Anti-HBc
FDA PMA · Qualitative and Quantitative Hepatitis B Virus Antibody assays · DiaSorin, Inc.
Key facts
| PMA number | P180038 |
|---|---|
| Trade name | LIAISON XL MUREX Anti-HBc, LIAISON MUREX Control Anti-HBc |
| Generic name | Qualitative and Quantitative Hepatitis B Virus Antibody assays |
| Applicant | DiaSorin, Inc. |
| Owner/operator | DiaSorin Inc. |
| Product code | SEI |
| Approval date | Jan 2, 2020 |
| Docket number | 20M-0107 |
| Notice date | Jan 8, 2020 |
| Establishment registration | 2182595 |
| FEI number | 2182595 |
At a glance
- 10–99 Supplements
- Oct 10, 2025 Latest supplement decision
- No Withdrawn
- Yes Summary of safety and effectiveness on file
- 1–9 UDI device identifiers (GUDID)
- None MAUDE adverse event reports
- None Recall events
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMA approvals
Premarket approval (PMA) is the FDA's most stringent review pathway, required for most Class III devices that support or sustain life or present a potentially unreasonable risk.
Source: U.S. Food and Drug Administration (FDA), Premarket Approval (PMA) database · Source date: